预防HBV感染的重要性--国际肝病采访Pawlotsky教授

帅庭

[/url]     Hepatology Digest: How can we prevent the re-infection of hepatitis B after liver transplantation? Is it possible that the newer drugs, such as entecavir and tenofovir, might have some advantages in this area?
  《国际肝病》: 在肝移植后如何预防HBV的再感染？恩替卡韦和替诺福韦等新药物，在这方面是否具有优势？

    Prof. Pawlotsky: There is no doubt about that. I think the two best modes of prevention, they are not mutually exclusive but very complimentary, are the use of immunoglobulins (HBIG) and specific antivirals. So far the experience has been with lamivudine, which is not the most potent drug and is a drug which is associated with some resistance. I do believe that the combination of HBIG and either entecavir or tenofovir would certainly be the solution for the best prevention of occurrence after liver transplantation. .

     Pawlotsky教授: 这一点是毫无疑问的。我认为肝移植后预防HBV的再感染有两种最好的方法，即使用免疫球蛋白(HBIG)和特异性抗病毒药物，这两种方法不是互相排斥的，而是互补的。到目前为止，拉米夫定已被用于预防再感染，它不是最有效的抗病毒药物，且具有一定的耐药性。我相信，将免疫球蛋白与恩替卡韦或者替诺福韦联合使用一定会更好地预防肝移植后HBV的再感染。
精彩内容请点击[url]http://www.ihepa.com/Special/ILC2008/Anydisp.asp?f=265&id=1119